Andrew Cunningham
Hoofd Techniek/Wetenschap/O&O bij CALCIMEDICA, INC.
Actieve functies van Andrew Cunningham
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| CALCIMEDICA, INC. | Hoofd Techniek/Wetenschap/O&O | 23-05-2023 | - |
Loopbaan van Andrew Cunningham
Eerdere bekende functies van Andrew Cunningham
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| TAYSHA GENE THERAPIES, INC. | Corporate Officer/Principal | 01-02-2021 | 01-04-2022 |
| REATA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-07-2018 | 01-02-2021 |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Corporate Officer/Principal | 01-08-2017 | 01-07-2018 |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Corporate Officer/Principal | 01-12-2012 | 01-06-2014 |
Opleiding van Andrew Cunningham
| University College Dublin | Masters Business Admin |
Statistieken
Internationaal
| Verenigde Staten | 4 |
| Japan | 2 |
| Verenigd Koninkrijk | 2 |
Operationeel
| Corporate Officer/Principal | 4 |
| Chief Tech/Sci/R&D Officer | 1 |
| Masters Business Admin | 1 |
Sectoraal
| Health Technology | 6 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| CALCIMEDICA, INC. | Health Technology |
| TAYSHA GENE THERAPIES, INC. | Health Technology |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
- Beurs
- Insiders
- Andrew Cunningham
- Ervaring
